Motzer, R. J., Porta, C., Vogelzang, N. J., Sternberg, C. N., Szczylik, C., Zolnierek, J., . . . Escudier, B. (2014). Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial. Lancet Oncol.
Παραπομπή Chicago StyleMotzer, Robert J., et al. "Dovitinib Versus Sorafenib for Third-line Targeted Treatment of Patients With Metastatic Renal Cell Carcinoma: An Open-label, Randomised Phase 3 Trial." Lancet Oncol 2014.
Παραπομπή MLAMotzer, Robert J., et al. "Dovitinib Versus Sorafenib for Third-line Targeted Treatment of Patients With Metastatic Renal Cell Carcinoma: An Open-label, Randomised Phase 3 Trial." Lancet Oncol 2014.
Πρόσοχή: Οι παραπομπές μπορεί να μην είναι 100% ακριβείς.